Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 5Phase 1/2 2Phase 2/3 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 78Cyclophosphamide 55Specimen Handling 53Carboplatin 49fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Gemcitabine 37Biopsy 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Cisplatin 24Pemetrexed 23Ipilimumab 22Capecitabine 21Temozolomide 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Fulvestrant 18Cetuximab 18Azacitidine 17Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × veliparib × 90 days × Clear all
NCT01386385 2026-05-26

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
53 enrolled 21 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT01012817 2026-04-29

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
88 enrolled 23 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡